Target therapy in metastatic pheochromocytoma: current perspectives and controversies
Most of the pheochromocytomas (PCCs) are benign neoplasms, but when they are malignant, they can be difficult to treat. Despite advances in diagnosis and imaging, it remains an untreatable tumor, when metastases develop. A deeper understanding of the alteration of the specific molecular pathways cau...
Main Authors: | Amrallah A. Mohammed, Ayman M. El-Shentenawy, Mohamed A. Sherisher, Hani M. El-Khatib |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-09-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/249 |
Similar Items
-
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
by: Camilo Jimenez, et al.
Published: (2020-08-01) -
Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches
by: Mickey J. M. Kuo, et al.
Published: (2022-07-01) -
Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?
by: Camilo Jimenez, et al.
Published: (2022-01-01) -
Performances of Functional and Anatomic Imaging Modalities in <i>Succinate Dehydrogenase A-</i>Related Metastatic Pheochromocytoma and Paraganglioma
by: Mayank Patel, et al.
Published: (2022-08-01) -
Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma—Case Report and Review of the Literature
by: Anli Tong, et al.
Published: (2020-02-01)